Letter: Safety after cessation of nucleos(t)ide analogue therapy in patients with chronic hepatitis B infection

Letter: Safety after cessation of nucleos(t)ide analogue therapy in patients with chronic hepatitis B infection—Authors' reply

Published:2023-09-13 Issue:7 Volume:58 Page:733-734
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Hsu Yao‐Chun¹²³^ORCID,Nguyen Mindie H.⁴⁵^ORCID,Wu Chun‐Ying³⁶

Affiliation:

1. Center for Liver Diseases and Department of Medical Research E‐Da Hospital Kaohsiung Taiwan

2. School of Medicine College of Medicine, I‐Shou University Kaohsiung Taiwan

3. Institute of Biomedical Informatics, National Yang Ming Chiao Tung University Taipei Taiwan

4. Division of Gastroenterology and Hepatology Stanford University Medical Center Palo Alto California USA

5. Department of Epidemiology and Population Health Stanford University Medical Center Palo Alto California USA

6. Division of Translational Research, Department of Medical Research Taipei Veterans General Hospital Taipei Taiwan

Abstract

LINKED CONTENTThis article is linked to Hsu et al papers. To view these articles, visit https://doi.org/10.1111/apt.17614 and https://doi.org/10.1111/apt.17657

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/apt.17681

Reference9 articles.

1. Combining hepatitis B core-related and surface antigens at end of nucleos(t)ide analogue treatment to predict off-therapy relapse risk

2. Severe hepatitis B flares with hepatic decompensation after withdrawal of nucleos(t)ide analogues: A population‐based cohort study

3. Differential Relapse Patterns After Discontinuation of Entecavir vs Tenofovir Disoproxil Fumarate in Chronic Hepatitis B

4. Incidence of Hepatic Decompensation After Nucleos(t)ide Analog Withdrawal: Results From a Large, International, Multiethnic Cohort of Patients With Chronic Hepatitis B (RETRACT-B Study)

5. Earlier and higher rate of hepatitis B virus relapse after discontinuing tenofovir versus entecavir in hepatitis B e antigen‐positive patients;Chen CH;J Infect Dis,2022